La cadena de opciones muestra datos clave de las opciones de acciones de Estrella Immunopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Estrella Immunopharma..

Estrella Immunopharma (NASDAQ:ESLA) Bolsa, Cadena de Opciones

Estrella Immunopharma

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma Inc

<p><a href="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars" title="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars">https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars</a></p>
<p>&nbsp;</p>
<p>Nvidia Aims To Rival AWS With Cloud Services And Software Business; OpenAI Develops Server Chips And Browser To Reduce Nvidia And Google Dependence; Elon Musk Builds Massive Supercomputing Cluster For Conversational AI; Major Tech Firms Race To Expand AI Hardware And Software Stacks Amid Intensifying Competition And Efforts To Reduce Supplier Reliance</p>


News

MSFT

NVDA

'OpenAI, Nvidia And Their Rivals Expand AI Turf Wars' - The Information

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Boeing</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Boeing.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $323,005, and 23 are calls, for a total amount of $880,234.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $200.0 for Boeing over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Boeing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Boeing's significant trades, within a strike price range of $140.0 to $200.0, over the past month.</p>
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967838_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$36.5</td>
<td>$30.9</td>
<td>$30.9</td>
<td>$200.00</td>
<td>$154.5K</td>
<td>1.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$185.00</td>
<td>$113.9K</td>
<td>1.2K</td>
<td align="right">821</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.8</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$170.00</td>
<td>$52.7K</td>
<td>11.1K</td>
<td align="right">85</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$150.00</td>
<td>$50.1K</td>
<td>2.8K</td>
<td align="right">812</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$48.2</td>
<td>$47.7</td>
<td>$48.2</td>
<td>$140.00</td>
<td>$48.2K</td>
<td>103</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Boeing</h3>
<p>Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.</p>
<p>In light of the recent options history for Boeing, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>With a volume of 1,879,101, the price of BA is down -0.28% at $176.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Boeing</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $190.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Boeing, which currently sits at a price target of $190. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Check Out What Whales Are Doing With Boeing

Trading Ideas

DRCT

Direct Digital Holdings Shares Halted To The Upside; Stock Now Up 143.64%

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>ServiceNow</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NOW, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for ServiceNow.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 21% bullish and 64%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $130,910, and 11 are calls, for a total amount of $1,080,381.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $1140.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of ServiceNow stands at 47.88, with a total volume reaching 98.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $230.0 to $1140.0, throughout the last 30 days.</p>
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967832_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$280.6</td>
<td>$272.5</td>
<td>$272.5</td>
<td>$850.00</td>
<td>$545.0K</td>
<td align="right">49</td>
<td align="right">20</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$861.7</td>
<td>$848.5</td>
<td>$855.58</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$862.1</td>
<td>$855.3</td>
<td>$855.3</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$399.8</td>
<td>$393.8</td>
<td>$397.93</td>
<td>$700.00</td>
<td>$79.5K</td>
<td align="right">11</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$321.8</td>
<td>$315.6</td>
<td>$315.6</td>
<td>$860.00</td>
<td>$63.1K</td>
<td align="right">80</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>In light of the recent options history for ServiceNow, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>ServiceNow's Current Market Status</h3>
<ul>
<li>Trading volume stands at 86,368, with NOW's price down by -1.13%, positioned at $1078.87.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With NOW

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Exxon Mobil</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with XOM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Exxon Mobil.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 22% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $141,045, and 5 are calls, for a total amount of $265,371.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $115.0 for Exxon Mobil, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Exxon Mobil's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Exxon Mobil's whale activity within a strike price range from $42.5 to $115.0 in the last 30 days. </p>
<h3>Exxon Mobil Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967826_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$100.1K</td>
<td>2.6K</td>
<td align="right">186</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$65.25</td>
<td>$61.1</td>
<td>$63.13</td>
<td>$42.50</td>
<td>$63.1K</td>
<td>3</td>
<td align="right">0</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$6.95</td>
<td>$110.00</td>
<td>$49.3K</td>
<td>16.0K</td>
<td align="right">58</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.1</td>
<td>$7.95</td>
<td>$8.02</td>
<td>$100.00</td>
<td>$40.1K</td>
<td>837</td>
<td align="right">50</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$6.92</td>
<td>$110.00</td>
<td>$34.6K</td>
<td>16.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Exxon Mobil</h3>
<p>ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners with a total global refining capacity of 4.5 million barrels of oil per day and is one of the world's largest manufacturers of commodity and specialty chemicals.</p>
<p>Following our analysis of the options activities associated with Exxon Mobil, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Exxon Mobil Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,980,999, with XOM's price down by -0.4%, positioned at $105.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Expert Opinions on Exxon Mobil</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $123.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $115.<br />
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Exxon Mobil, maintaining a target price of $115.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Exxon Mobil, maintaining a target price of $127.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Exxon Mobil with a target price of $125.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Exxon Mobil, targeting a price of $134. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Exxon Mobil, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In XOM Options

<p>Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 18.39%. Currently, Imperial Oil has a market capitalization of $32.81 billion. </p>
<p><strong>Buying $1000 In IMO:</strong> If an investor had bought $1000 of IMO stock 5 years ago, it would be worth <strong>$2,314.74</strong> today based on a price of $61.23 for IMO at the time of writing.</p>
<h3>Imperial Oil's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967823_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<p>Kevin O&#8217;Leary, the well-known entrepreneur and <a href="https://www.benzinga.com/news/24/12/42559810/people-think-kevin-oleary-is-the-mean-shark-but-he-says-im-not-mean-i-just-tell-the-truth-to-keep-families-from-going-broke">investor from Shark Tank</a>, has weighed in on why so many tech CEOs and business leaders are suddenly cozying up to President-elect Donald Trump. During a recent <a href="https://www.youtube.com/watch?v=oML1qbX1_uM">interview</a> on Fox &amp; Friends, O&#8217;Leary said it's not just about Trump's corporate tax policies – the real reason is deregulation.</p>
<p>For context, Trump's policies, such as maintaining the 21% corporate tax rate, undoubtedly appeal to businesses. However, according to O'Leary, the bigger draw is Trump's commitment to cutting federal red tape, making it easier for businesses to grow and operate without constant legal battles and administrative hurdles.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>
<p>O&#8217;Leary pointed out that federal deregulation under Trump's administration is particularly attractive to companies involved in <a href="https://www.benzinga.com/calendars/m-a">mergers and acquisitions</a>. He noted that Trump will "cool off all these pursuits and change many of the administrative rules that make it harder to get things done."</p>
<p>In simple terms, businesses see Trump as someone who will make it easier for them to operate without worrying about constant interference from regulators. That's a huge selling point for companies looking to expand or innovate.</p>
<h2 class="wp-block-heading">CEOs See Trump as &#8216;The Guy&#8217;</h2>
<p>O&#8217;Leary was direct about why CEOs are eager to meet with Trump. &#8220;They're not stupid,&#8221; he said. &#8220;They're saying, &#8216;Well, I think I'm going to go suck up with him because he's the guy for sure for the next two years.'&#8221;</p>
<p><strong>See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></p>
<p>This isn't just about tech leaders like Mark Zuckerberg or Jeff Bezos. O&#8217;Leary said leaders from various industries – and even other countries – are lining up to meet with Trump, recognizing his influence and power in shaping business policy.</p>
<h2 class="wp-block-heading">Donations for Trump&#8217;s Inauguration</h2>
<p>Mark Zuckerberg and <a href="https://www.benzinga.com/tech/24/12/42479253/jeff-bezos-amazon-pledges-1-million-to-trumps-inaugural-event-following-in-the-footsteps-of-mark-zuckerberg-and-meta">Jeff Bezos have each contributed $1 million</a> through their companies, Meta Platforms and Amazon. OpenAI CEO Sam Altman is joining them, making a <a href="https://www.benzinga.com/news/management/24/12/42485193/sam-altman-to-donate-1m-to-trumps-inauguration-fund-following-zuckerberg-bezos-eager-to-support">personal donation of $1 million</a>. Perhaps surprisingly, the trading platform Robinhood has donated $2 million.</p>
<p>O&#8217;Leary highlighted that these donations represent a shift in attitude among business leaders. This is about aligning with Trump's vision for the economy and acknowledging his dominance in shaping the future of policy.&nbsp;</p>
<p><strong>Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>Altman, for instance, has publicly praised Trump's commitment to advancing AI infrastructure, a sentiment echoed by other tech leaders. &#8220;President Donald Trump will lead our country into the age of AI and I am eager to support his efforts to ensure America stays ahead,&#8221; he said.</p>
<p>The President-elect&#8217;s ability to remove regulatory roadblocks has made him an attractive ally for business leaders, regardless of their personal opinions about him.</p>
<h2 class="wp-block-heading">Why Deregulation Can Be Harmful</h2>
<p>While <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">deregulation is a win for businesses</a>, it can also result in significant drawbacks. <a href="https://www.imf.org/external/pubs/ft/wp/2013/wp13247.pdf">Reduced oversight</a> often opens the door to harmful practices, such as environmental damage, compromised safety standards and unfair labor practices. It can also mean fewer consumer protections, which could let businesses focus more on profits than on doing what's right for people.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.26/share!</strong></a></strong></li>
</ul>


Kevin O'Leary Says Deregulation Is The Real Reason Everybody Is 'Sucking Up To Trump Now,' Not Lower Taxes

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>Weyerhaeuser Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for <strong>Aclaris Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded <strong>GCM Grosvenor Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>PotlatchDeltic Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying WY stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Upgrades

Price Target

Analyst Ratings

ACRS

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

<p><strong>Rumble Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced it entered into a definitive agreement for a $775 million strategic investment from <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know"><strong>Tether</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)</a>.</p>
<p><strong>The Details:</strong> Rumble on Friday announced that Tether plans to buy 103.33 million shares of its common stock for $7.50 per share, representing $775 million in gross proceeds. Tether offers the most widely used dollar <a href="https://www.benzinga.com/topic/stablecoins">stablecoin</a> with more than 350 million users. </p>
<p>Rumble plans to use $250 million of the gross proceeds to support growth initiatives, while the remaining funds will be used for a self-tender offer of up to 70 million Rumble shares at the same price as Tether&#8217;s investment.</p>
<p>Rumble CEO <strong>Chris Pavlovski</strong> does not intend to sell more than 10 million shares of common stock in the tender offer. He will retain his controlling stake in the company.</p>
<p>&#8220;I could not be more excited about this collaboration with Tether for a number of reasons. First, many people may not realize the incredibly strong connection between the cryptocurrency and free speech communities, which is rooted in a passion for freedom, transparency, and decentralization,&#8221; Pavlovski said.</p>
<p>&#8220;Second, the immediate commitment of adding $250 million in cash to our balance sheet not only confirms the level of support and commitment to a collaboration between our companies, it also fuels our growth initiatives. And, third, this transaction provides an immediate liquidity event for all of our stockholders who elect to participate in the self tender offer.&#8221;</p>
<p>Rumble&#8217;s existing board and governance structure, including Pavlovski&#8217;s super-majority voting control, will remain unchanged following the closing of the transaction. </p>
<p>Tether will own a minority position in Rumble&#8217;s outstanding common stock, but will not have the right to designate any members of the board. The investment and tender offer are expected to close during the first quarter of 2025. </p>
<p><strong>Related Link: <a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a></strong></p>
<p><strong>RUM Price Action</strong>: At the time of writing, Rumble shares were up 79.8% at $12.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Shutterstock.</em></p>


Movers

$USDT

Rumble Stock Is Ripping Higher Monday: What's Going On?

<p>Truist Securities  analyst Joon Lee   maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $460.</p>


VRTX

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $460

Direct Digital Shares Resume Trade

Direct Digital Shares Halted On Circuit Breaker To The Upside, Stock Now Up 98.2%

<p>Loop Capital  analyst Mark Schappel   maintains E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) with a Hold and lowers the price target from $4 to $3.</p>


ETWO

Loop Capital Maintains Hold on E2open Parent Holdings, Lowers Price Target to $3

QBTS

D-Wave Quantum Option Alert: Fri $8 Calls Sweep (39) Near The Ask: 2000 @ $0.7 Vs 2525 OI; Ref=$7.48

<p>High-rolling investors have positioned themselves bearish on Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in RGTI often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 17 options trades for Rigetti Computing. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 23% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $27,700, and 16 calls, totaling $1,630,393.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $20.0 for Rigetti Computing over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Rigetti Computing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rigetti Computing's whale trades within a strike price range from $10.0 to $20.0 in the last 30 days. </p>
<h3>Rigetti Computing Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734966934_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$3.4</td>
<td>$2.4</td>
<td>$2.35</td>
<td>$12.50</td>
<td>$540.5K</td>
<td>416</td>
<td>2.3K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$16.00</td>
<td>$288.4K</td>
<td>93</td>
<td>2.0K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.1</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$13.00</td>
<td>$120.0K</td>
<td>4.9K</td>
<td>859</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$10.00</td>
<td>$120.0K</td>
<td>7.6K</td>
<td>1.3K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.7</td>
<td>$1.7</td>
<td>$3.7</td>
<td>$10.00</td>
<td>$90.6K</td>
<td>7.6K</td>
<td>245</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rigetti Computing</h3>
<p>Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.</p>
<p>Following our analysis of the options activities associated with Rigetti Computing, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Rigetti Computing</h3>
<ul>
<li>With a volume of 89,179,572, the price of RGTI is up 24.69% at $11.68. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 80 days.</li>
</ul>
<h3>What The Experts Say On Rigetti Computing</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $8.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Craig-Hallum downgraded its action to Buy with a price target of $12.<br />
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Rigetti Computing, maintaining a target price of $4. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rigetti Computing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RGTI

A Closer Look at Rigetti Computing's Options Market Dynamics

<p>High-rolling investors have positioned themselves bearish on Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ACHR often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Archer Aviation. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 40% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $28,000, and 9 calls, totaling $405,742.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $10.0 for Archer Aviation during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Archer Aviation's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Archer Aviation's whale activity within a strike price range from $5.0 to $10.0 in the last 30 days. </p>
<h3>Archer Aviation Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734966927_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$5.00</td>
<td>$62.0K</td>
<td>4.9K</td>
<td align="right">112</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$5.00</td>
<td>$57.0K</td>
<td>18.7K</td>
<td align="right">127</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.6</td>
<td>$2.45</td>
<td>$2.6</td>
<td>$7.50</td>
<td>$52.0K</td>
<td>0</td>
<td align="right">400</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.7</td>
<td>$4.4</td>
<td>$4.49</td>
<td>$7.00</td>
<td>$51.6K</td>
<td>13.3K</td>
<td align="right">162</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.55</td>
<td>$2.3</td>
<td>$2.55</td>
<td>$7.50</td>
<td>$51.0K</td>
<td>0</td>
<td align="right">200</td>
</tr>
</tbody>
</table>
</p>
<h3>About Archer Aviation</h3>
<p>Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.</p>
<p>After a thorough review of the options trading surrounding Archer Aviation, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Archer Aviation Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 12,846,103, the ACHR's price is up by 1.37%, now at $9.62. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 63 days.</li>
</ul>
<h3>Expert Opinions on Archer Aviation</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $12.875.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Archer Aviation, which currently sits at a price target of $11.<br />
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on Archer Aviation with a target price of $12.<br />
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on Archer Aviation, maintaining a target price of $13.<br />
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Archer Aviation with a target price of $15. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Archer Aviation with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


ACHR

Looking At Archer Aviation's Recent Unusual Options Activity

<p>Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 5 years by 11.47% on an annualized basis producing an average annual return of 24.3%. Currently, Arthur J. Gallagher has a market capitalization of $70.24 billion. </p>
<p><strong>Buying $1000 In AJG:</strong> If an investor had bought $1000 of AJG stock 5 years ago, it would be worth <strong>$2,973.93</strong> today based on a price of $281.19 for AJG at the time of writing.</p>
<h3>Arthur J. Gallagher's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734966921_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<p>Financial giants have made a conspicuous bullish move on Rumble. Our analysis of options history for Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) revealed 19 unusual trades.</p>
<p>Delving into the details, we found 52% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $55,000, and 17 were calls, valued at $986,487.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2.0 and $20.0 for Rumble, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Rumble's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rumble's whale activity within a strike price range from $2.0 to $20.0 in the last 30 days. </p>
<h3>Rumble Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734966920_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.45</td>
<td>$1.4</td>
<td>$1.45</td>
<td>$10.00</td>
<td>$287.2K</td>
<td>14.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>RUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.9</td>
<td>$7.0</td>
<td>$9.27</td>
<td>$4.00</td>
<td>$92.7K</td>
<td>203</td>
<td>102</td>
</tr>
<tr>
<td>RUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.8</td>
<td>$6.00</td>
<td>$92.1K</td>
<td>2.2K</td>
<td>146</td>
</tr>
<tr>
<td>RUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.1</td>
<td>$0.6</td>
<td>$1.1</td>
<td>$20.00</td>
<td>$55.0K</td>
<td>7.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>RUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$5.6</td>
<td>$2.9</td>
<td>$4.79</td>
<td>$10.00</td>
<td>$47.9K</td>
<td>3.2K</td>
<td>102</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rumble</h3>
<p>Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.</p>
<p>Having examined the options trading patterns of Rumble, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Rumble Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 15,643,881, the RUM's price is up by 65.58%, now at $11.9. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 93 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rumble with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Market Whales and Their Recent Bets on RUM Options

<p>President-elect<strong> Donald Trump</strong> has reignited trans-Atlantic trade tensions, demanding the European Union buy more U.S. oil and liquefied natural gas (LNG) <a href="https://www.benzinga.com/topic/tariffs">or face sweeping tariffs. </a></p>
<p>The U.S. is already Europe's largest energy supplier. Questions remain over whether Trump&#8217;s ultimatum will escalate into a broader trade war.</p>
<p>"I told the European Union that they must make up their tremendous deficit with the United States by the large-scale purchase of our oil and gas. Otherwise, it is TARIFFS all the way!!!" Trump wrote Friday on his social media platform, Truth Social.</p>
<p>U.S. natural gas prices — tracked by the <strong>United States Natural Gas Fund LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) — has risen by 25% since Trump&#8217;s election victory in November.</p>
<h3 class="wp-block-heading">US LNG: A Major Player In Europe's Energy Crisis</h3>
<p>The U.S. delivered 47 million tons (mt) of LNG over the past year (December 2023–November 2024), accounting for 51% of total U.S. LNG exports and 46% of Europe's LNG imports.</p>
<p>This surge in trade reflects a sharp pivot in Europe's energy strategy following the 2022 energy crisis sparked by Russia's invasion of Ukraine and subsequent sanctions on Moscow.</p>
<p>Goldman Sachs data shows that U.S. LNG deliveries to Europe rose 197% during the crisis, while shipments to non-European destinations fell by 41%.</p>
<p>According to Samantha Dart, commodity analyst at Goldman Sachs, this reallocation was made possible by the flexible destination clauses in U.S. LNG contracts, which allow buyers to redirect cargoes to the most lucrative markets.</p>
<p>"The US is not only Europe's largest LNG supplier but also the primary source of future LNG import growth for the region," Dart said, citing long-term contracts signed since the start of the Ukraine war. </p>
<p>These agreements amount to nearly 16 million tons per annum (mtpa), making the US the top global supplier in terms of contracted European LNG volumes.</p>
<h3 class="wp-block-heading">Can US LNG Fully Replace Russian Gas?</h3>
<p>Theoretically, U.S. LNG could replace Russia's 17 mt of annual LNG exports to Europe, according to Goldman Sachs.</p>
<p>However, Dart indicating that such a shift would likely come with higher costs for European buyers.</p>
<p>"The reallocation of US LNG cargoes to Europe could lead to higher freight costs and elevated European import prices to motivate the rerouting of shipments originally destined for other regions," Dart said. </p>
<p>She added that such a move would have "little to no impact" on total U.S. LNG export volumes, given that US liquefaction capacity is already operating at its limit.</p>
<p>Goldman Sachs also highlighted that expanding U.S. LNG export capacity would take time, with new liquefaction facilities unlikely to come online before 2027 or 2028.</p>
<p>This timeline significantly limits the potential for a near-term increase in U.S. LNG exports to meet Europe's energy needs.</p>
<p>Yet, Europe's climate agenda may limit its willingness to commit to additional long-term LNG deals. "Europe's decarbonization goals might limit European companies' appetite for long-term commitments to grow natural gas use," Dart said. </p>
<h3 class="wp-block-heading">Tariffs As A Trump Negotiation Strategy</h3>
<p>Trump's renewed focus on tariffs aligns with his broader economic agenda. During his first term, he used tariffs to push for concessions from trading partners, targeting allies like Canada, Mexico, and South Korea, as well as adversaries like China.</p>
<p>For example, during the 2018-2019 trade war with China, Beijing retaliated with LNG tariffs, causing US exports to collapse. It wasn't until 2020's Phase 1 trade deal that China resumed buying US LNG, signing long-term contracts that have since helped fund new US liquefaction projects.</p>
<p>Similar dynamics could play out with Europe if Trump's tariffs escalate. But unlike China, Europe may struggle to justify long-term LNG deals given its climate goals and reliance on diverse energy suppliers.</p>
<p><strong>Read now: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42603073/natural-gas-nears-2-year-highs-inflation-fears-mount-as-utility-costs-climb-3-energy-stocks-rise">Natural Gas Nears 2-Year Highs, Inflation Fears Mount As Utility Costs Climb</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Eurozone

Commodities

ETFs

Tariffs Or More Energy: Analyst Warns Of High Costs, Limited Capacity If Europe Bows To Trump's LNG Push

<p>U.S. stocks were lower, with the Dow Jones index falling over 300 points on Monday.</p>
<p>Shares of <strong>Honda Motor Co., Ltd</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) rose sharply during Monday's session after the company announced it agreed to begin discussions and consideration toward a business <a href="https://www.benzinga.com/24/12/42642773/honda-nissan-start-merger-talks">integration with Nissan Motor.</a></p>
<p>Nissan and Honda are planning to establish a joint holding company that will serve as the parent company for both Nissan and Honda. The joint holding parent company will be listed on the Tokyo Stock Exchange and Nissan and Honda will subsequently be delisted. The listing of the joint holding company is scheduled for August 2026.</p>
<p>Honda Motor shares jumped 13.5% to $27.13 on Monday.</p>
<p>Here are some other big stocks recording gains in today's session.</p>
<ul>
<li><strong>Rumble Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares jumped 75% to $12.59 after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</li>
<li><strong>Despegar.com, Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) gained 32.2% to $19.36. The company announced it will be acquired by Prosus in $1.7 Billion deal.</li>
<li><strong>Anavex Life Sciences Corp</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) surged 32.2% to $11.47 following fourth-quarter results. The company's Alzheimer&#8217;s Drug Blarcamesine was accepted for a review by European regulators.</li>
<li><strong>Playa Hotels &amp; Resorts N.V.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) gained 28.8% to $12.38 after Hyatt Hotels disclosed it executed an exclusivity agreement to potentially acquire the company.</li>
<li><strong>Rigetti Computing, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares rose 21.8% to $11.42. The company announced it has launched its 84-Qubit Ankaa 3 System and achieved 99.5% Median Two-Qubit Gate Fidelity Milestone.</li>
<li><strong>Red Cat Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) surged 14.6% to $12.32.</li>
<li><strong>D-Wave Quantum Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) gained 13.2% to $7.29.</li>
<li><strong>New Fortress Energy Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) rose 10.7% to $13.24 after Stifel maintained a Buy rating and raised its price target from $16 to $17.</li>
<li><strong>FormFactor, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) gained 6% to $45.32.</li>
<li><strong>Broadcom Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) rose 3.9% to $228.60.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Intraday Update

AVGO

AVXL

DESP

FORM

PLYA

RCAT

Honda Motor, Rumble, Despegar.com And Other Big Stocks Moving Higher On Monday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>We&rsquo;re starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!</p>



<p>Moving stocks are investments, acquisitions, new agreements and more.</p>



<p>Let&rsquo;s get into that news down</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Volcon </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/"><strong>VLCN</strong></a>) stock is rocketing more than 71% with heavy trading on <strong>Empery Asset Management, LP</strong> <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981363&amp;type=PDF&amp;symbol=VLCN&amp;cdn=0a561d788a48501f1c170c0f63b65ac5&amp;companyName=Volcon+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-01-11">taking a stake in the company</a>.</li>



<li><strong>Charge Enterprises</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/"><strong>CRGE</strong></a>) shares are soaring over 41% with strong early morning trading.</li>



<li><strong>Aeries Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aert-stock-quote/"><strong>AERT</strong></a>) stock is surging more than 35% alongside heavy trading this morning.</li>



<li><strong>Jet AI </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/"><strong>JTAI</strong></a>) shares are increasing over 20% as it also sees strong trading on Friday morning.</li>



<li><strong>Aileron Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/"><strong>ALRN</strong></a>) stock is gaining more than 18% following its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981539&amp;type=PDF&amp;symbol=ALRN&amp;cdn=2219d39279c110c1197b97762ea29d5d&amp;companyName=Aileron+Therapeutics+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-11">acquisition of Lung Therapeutics</a>.</li>



<li><strong>Hyperfine</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hypr-stock-quote/"><strong>HYPR</strong></a>) shares are heading over 16% higher without any clear news this morning.</li>



<li><strong>Akso Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/"><strong>AHG</strong></a>) stock is climbing more than 14% today.</li>



<li><strong>Emcore </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/"><strong>EMKR</strong></a>) shares are jumping over 13% with a <a href="https://www.nasdaq.com/press-release/emcore-corporation-enters-into-cooperation-agreement-with-bradley-l.-radoff-2024-01">new cooperation agreement</a>.</li>



<li><strong>Apollomics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/"><strong>APLM</strong></a>) stock is rising more than 13% this morning.</li>



<li><strong>Safe &amp; Green Development</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/"><strong>SGD</strong></a>) shares are up over 13% on Friday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Estrella Immunopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a>) stock is crashing more than 46% without any obvious news.</li>



<li><strong>Genius </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/"><strong>GNS</strong></a>) shares are plummeting over 34% after <a href="https://www.nasdaq.com/press-release/genius-group-announces-pricing-of-%248.25-million-public-offering-2024-01-12">pricing a public offering</a>.</li>



<li><strong>VCI Global</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcig-stock-quote/"><strong>VCIG</strong></a>) stock is diving more than 27% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317975438&amp;type=PDF&amp;symbol=VCIG&amp;cdn=d1e913c93adb43c9620f5e05d59906d8&amp;companyName=VCI+Global+Limited&amp;formType=F-1%2FA&amp;formDescription=%5BAmend%5D+Registration+statement+for+certain+foreign+private+issuers&amp;dateFiled=2024-01-08">a public offering</a>.</li>



<li><strong>SealSQ </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/laes-stock-quote/"><strong>LAES</strong></a>) shares are taking an over 20% beating <a href="https://www.globenewswire.com/news-release/2024/01/10/2807169/0/en/SEALSQ-Announces-FY-2023-Preliminary-Unaudited-Revenue-of-30-Million-Marking-a-29-Increase-Over-FY-2022.html">alongside preliminary earnings</a>.</li>



<li><strong>Future FinTech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ftft-stock-quote/"><strong>FTFT</strong></a>) stock is tumbling more than 13% following <a href="https://www.marketwatch.com/story/future-fintech-stock-drops-13-after-sec-charges-ceo-68d81977">charges against its CEO</a>.</li>



<li><strong>Vivopower </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/"><strong>VVPR</strong></a>) shares are sliding over 12% after its <a href="https://www.marketwatch.com/story/vivopower-international-shares-rise-after-subsidiary-tembo-meets-milestones-for-strategic-direct-equity-investment-05502abe">subsidiary met certain milestones</a>.</li>



<li><strong>Tarena International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock is decreasing more than 11% this morning.</li>



<li><strong>MAIA Biotechnology</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/"><strong>MAIA</strong></a>) shares are dropping over 11% on Friday.</li>



<li><strong>Exicure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/"><strong>XCUR</strong></a>) stock is falling more than 9% without any news to report.</li>



<li><strong>Eightco </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/"><strong>OCTO</strong></a>) shares close out our pre-market stock movers down close to 9%.</li>
</ol><p><em>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> that will provide high returns this year, with their new advances.</p>



<h2><strong>Catalyst Pharmaceuticals (CPRX)</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>


<p><strong>Catalyst Pharmaceuticals </strong>(NASDAQ<strong>:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/"><strong>CPRX</strong></a></strong>) is a pharmaceutical company that focuses on licensing the rights to the cures of rare diseases. It has a valuation of $<a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX">14.36</a>, with a YoY decrease of <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX&amp;window=1Y">28.70%</a>. However, it appears to be poised for growth.</p>



<p>Although Catalyst has consistently <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">missed earnings estimates</a> by small margins, 4 <em>Yahoo Finance!</em> investors have given it a <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">buy rating</a>. Additionally, 5 analysts have given it a price target of <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">$26.20</a>, far above its current valuation. It has a debt of $3.64 million, with a free cash flow of $120.97 million. This gives it plenty of liquid assets to invest in the development of new drugs.</p>



<p>A few key drugs Catalyst has in its pipeline include drugs for <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer">Duchenne muscular dystrophy</a>. This disease will have a market of <a href="https://www.alliedmarketresearch.com/duchenne-muscular-dystrophy-market-A15646">$2.07 billion in 2031</a>, with a CAGR of 4.7%. This is much more than Catalyst&rsquo;s current market cap of <a href="https://finance.yahoo.com/quote/CPRX/key-statistics?p=CPRX">$1.69 billion</a>, showing potential for future growth. Additionally, sales for current drugs are expected to hold steady. This makes it one of those biotech stocks to consider.</p>



<p>Management is expected to continue buying the rights to and developing drugs for niche, in-demand disorders. This opens the possibility of future growth. Coupled with being perceived as undervalued at the moment, it becomes clear why Catalyst Pharmaceuticals is a stock you should invest in.</p>



<h2><strong>Estrella Immunopharma (ESLA)&nbsp;</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>


<p><strong>Estrella Immunopharma </strong>(NASDAQ:<strong><a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a></strong>)<strong> </strong>is an American biopharmaceutical company focusing on the development of T-cell therapies. Headquartered in Emeryville, CA, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$1.03</a>.&nbsp;</p>



<p>Developing innovative therapies for solid tumors using novel &ldquo;mark-and-kill&rdquo; methods, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$62.67</a> &mdash; down 14.17% in the past month.</p>



<p>Valued at <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$36.26 millio</a>n, the biopharmaceuticals market size is estimated at $516.79 billion in 2024 and is expected to reach $761.80 billion by 2029, growing at a <a href="https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry">CAGR </a>of 8.07% during the forecast period.</p>



<p>Financially, ESLA improved on almost every metric during Q3 2023. ESLA reported <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$-1.87 million</a> in net income, a YoY increase of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">35.17%</a>. Total assets also received a massive surge of $27.35 million increasing over<a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX"> 750%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for ESLA, with the company outperforming previous years on net change in cash, increasing 1,886.80% YoY. This increase in liquidity makes it one of those biotech stocks for investors to pay close attention to.</p>



<p>ESLA is set up for success through recent <a href="https://www.estrellabio.com/pipeline">research</a> in novel drugs and therapies. It is developing advanced T-cell therapies, particularly focusing on its CD19-Redirected ARTEMIS T Cells. This approach is being applied initially to high-risk blood cancers. As ESLA continues to include an emphasis on research and development, expect ESLA valuation to climb as more customers gravitate towards the company&rsquo;s products.</p>



<h2><strong>VolitionRX (VNRX)</strong></h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


<p><strong>VolitionRX </strong>(NYSEAMERICAN:<strong><a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/"><strong>VNRX</strong></a></strong>)<strong> </strong>is a biotech company that takes part in the creation of blood-based cancer tests, helping diagnose a range of cancers. The company is based in Henderson, NV, and has amassed a valuation of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$0.86</a> with a strong increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">48.88%</a> in just the last month.&nbsp;&nbsp;</p>



<p>VNRX is fully established in the market but still shows signs of future growth. Valued at <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$67.94 million</a> in 2023, The global biotechnology market size accounted for $368 Billion in 2021 and is anticipated to reach $1,334 Billion by 2030 with a <a href="https://www.linkedin.com/pulse/biotechnology-market-anticipated-reach-usd-1334-billion/">CAGR </a>of 15.5%. </p>



<p>Financially, VNRX improved on almost every metric during Q3 2023. VNRX reported <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$165.21K</a> in revenue, a YoY increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">405.02%</a>. Net profit margin also received massive surges of $-5.07K, increasing over <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">70%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for VNRX, with the company YoY outperforming EPS by 23.64%.&nbsp;</p>



<p>VNRX is set up for success through recent<a href="https://finance.yahoo.com/news/volition-vpg-launch-nu-q-112400172.html"> announcements</a> of closing on an aggregate of $5.5 m<a href="https://finance.yahoo.com/news/volitionrx-secures-approximately-5-5-130000482.html">illion</a> in financing from investors at Wallonie Entreprendre in Belgium. It has also recently partnered with leading laboratories in the UK and Ireland to launch a groundbreaking cancer test for the early detection and monitoring of cancer in dogs. As VNRX continues to include an emphasis on innovation, expect VNRX valuation to climb as more investors and clients gravitate towards the company&rsquo;s services.</p>



<p><em>On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>The researchers contributing to this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/01/next-big-thing-3-biotech-stocks-to-watch-for-groundbreaking-advances/">Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Estrella Immunopharma (ESLA) has shared an update. Estrella Immunopharma, Inc. has recently updated their investor presentation on their website, w...

Estrella Immunopharma Unveils Updated Investor Presentation

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Estrella Immunopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a></span>) just reported results for the third quarter of 2024.</p><ul><li>Estrella Immunopharma reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/esla-stock-earnings-estrella-immunopharma-for-q3-of-2024/">ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!</p>



<p>Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>VSee Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/"><strong>VSEE</strong></a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li><strong>Adagio Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/"><strong>ADGM</strong></a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li><strong>Akanda </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/"><strong>AKAN</strong></a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li><strong>Exicure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/"><strong>XCUR</strong></a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the <strong>Nasdaq Capital Market</strong>.</li>



<li><strong>Australian Oilseeds</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/"><strong>COOT</strong></a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li><strong>Tandem Diabetes Care</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/"><strong>TNDM</strong></a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li><strong>Vaccinex </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/"><strong>VCNX</strong></a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li><strong>AGBA Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/"><strong>AGBA</strong></a>) shares are climbing more than 13% without any clear news this morning.</li>



<li><strong>Venus Concept</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/"><strong>VERO</strong></a>) stock is jumping over 13% on Friday morning.</li>



<li><strong>Integral Ad Science</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/"><strong>IAS</strong></a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Gamer Pakistan</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/"><strong>GPAK</strong></a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li><strong>Fresh Vine Wine</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/"><strong>VINE</strong></a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li><strong>Conn&rsquo;s </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/"><strong>CONN</strong></a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li><strong>Greenlane </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/"><strong>GNLN</strong></a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li><strong>Procore Technologies</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/"><strong>PCOR</strong></a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li><strong>Estrella Immunopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/"><strong>ESLA</strong></a>) shares are sliding close to 21% on Friday morning.</li>



<li><strong>Intel </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/"><strong>INTC</strong></a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li><strong>Smith Micro Software</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/"><strong>SMSI</strong></a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li><strong>GraniteShares 2x Long AMZN Daily ETF</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/"><strong>AMZZ</strong></a>) stock is slipping over 17%.</li>



<li><strong>Snap </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/"><strong>SNAP</strong></a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The latest announcement is out from Estrella Immunopharma (ESLA). Estrella Immunopharma, Inc. has appointed Ms. Hong Zhang as the new Chairperson a...

Estrella Immunopharma Welcomes New Chairperson, Expands Board

Estrella Immunopharma ( ($ESLA) ) just unveiled an update. Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO ...

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO

Estrella Immunopharma files for $100M common stock, warrants offering

17:11 EST Estrella Immunopharma (ESLA) files $100M common stock, warrants offering Published first on TheFly – the ultimate source for real-time, m...

Comments

Estrella Immunopharma

Estrella Immunopharma (ESLA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL